Investigating how blood flow affects heart valve disease
Flow and endothelial signaling in acquired myxomatous valve disease
This study is looking at how changes in blood flow and certain genes in heart valve cells might lead to myxomatous valve disease (MVD), which affects the mitral valve, and it aims to help patients by uncovering new insights into how this condition develops.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10626893 on NIH RePORTER |
What this research studies
This research focuses on myxomatous valve disease (MVD), a condition that affects the heart's mitral valve, leading to complications like valve prolapse and regurgitation. The study aims to understand how changes in blood flow and specific gene expressions in heart valve cells contribute to the development of MVD. By using advanced genetic tools, researchers will explore the relationship between hemodynamic forces and the cellular behavior of heart valve cells, which could reveal new insights into the disease's progression. Patients may be involved in understanding how their unique heart conditions relate to these mechanisms.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with myxomatous valve disease or those experiencing mitral valve issues.
Not a fit: Patients with congenital heart defects or those who do not have any heart valve issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments or preventive strategies for patients with myxomatous valve disease.
How similar studies have performed: While the mechanisms of myxomatous valve disease are being explored, this specific approach focusing on hemodynamic effects and gene expression is relatively novel.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Kahn, Mark L — University of Pennsylvania
- Study coordinator: Kahn, Mark L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.